{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:59:59Z","timestamp":1773673199653,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-026-00420-3","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:26:48Z","timestamp":1772202408000},"page":"423-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Letter to the Editor Regarding: \u201cCost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician\u2019s Choice of Treatment in Spain\u201d"],"prefix":"10.1007","volume":"14","author":[{"given":"Kirsten J. M.","family":"van Nimwegen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"Morano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"420_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00333-7","author":"C Encinas","year":"2025","unstructured":"Encinas C, et\u00a0al. Cost-effectiveness of elranatamab versus current therapies for the management of patients with triple-class exposed, relapsed and refractory multiple myeloma, including other bispecific and physician\u2019s choice of treatment in Spain. Oncol Ther. 2025. https:\/\/doi.org\/10.1007\/s40487-025-00333-7.","journal-title":"Oncol Ther"},{"issue":"5","key":"420_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","volume":"65","author":"I Mol","year":"2024","unstructured":"Mol I, et\u00a0al. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma. Leuk Lymphoma. 2024;65(5):660\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"420_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41408-024-01160-1","volume":"14","author":"N van de Donk","year":"2024","unstructured":"van de Donk N, et\u00a0al. Impact of COVID-19 on outcomes with teclistamab in patients with relapsed\/refractory multiple myeloma in the phase 1\/2 MajesTEC-1 study. Blood Cancer J. 2024;14(1):186.","journal-title":"Blood Cancer J"},{"issue":"9","key":"420_CR4","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, et\u00a0al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"key":"420_CR5","unstructured":"Mohty M, et\u00a0al. MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. In: EHA. 2024."},{"key":"420_CR6","doi-asserted-by":"crossref","unstructured":"Leleu X, Raje N, Lesokhin A. Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3. In: EHA. 2023.","DOI":"10.1016\/S2152-2650(23)01448-9"},{"key":"420_CR7","doi-asserted-by":"crossref","unstructured":"van Nimwegen K, et\u00a0al. Evaluating the impact of censoring on progression-free survival comparisons of BCMA-targeting bispecific antibodies in relapsed\/refractory multiple myeloma. In: ISPOR EU, Glasgow. 2025.","DOI":"10.1016\/j.jval.2025.09.210"},{"issue":"6","key":"420_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1470-2045(24)00722-8","volume":"26","author":"T Olivier","year":"2025","unstructured":"Olivier T, Haslam A, Prasad V. The BREAKING-ICE app: an interactive journey into informative censoring. Lancet Oncol. 2025;26(6):693.","journal-title":"Lancet Oncol"},{"issue":"1","key":"420_CR9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1080\/13696998.2025.2514909","volume":"28","author":"LN Gordan","year":"2025","unstructured":"Gordan LN, et\u00a0al. Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States. J Med Econ. 2025;28(1):910\u201320.","journal-title":"J Med Econ"},{"key":"420_CR10","unstructured":"NICE. Single technology appraisal\u2014Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]. 2024."},{"key":"420_CR11","unstructured":"Medicinradet. Medicinradets anbefaling vedr teclistamab til behandling af patienter med knoglemarvskraeft, som har faet mindst tre tidligere behandlinslinjer. 2024. https:\/\/filer.medicinraadet.dk\/media\/2plk3ijp\/medicinradets-anbefaling-vedr-teclistamab-til-knoglemarvskraeft-vers-1-0x.pdf."},{"key":"420_CR12","doi-asserted-by":"crossref","unstructured":"Usmani SZ, et\u00a0al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. American Society of Clinical Oncology; 2023.","DOI":"10.1016\/S2152-2650(23)01410-6"},{"key":"420_CR13","unstructured":"Pfizer Inc. MAGNETISMM-3 an open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-cd38 antibody\u2014Final protocol amendment 10. 2023."},{"key":"420_CR14","unstructured":"European Medicines Agency. Elrexfio: summary of product characteristics. 2024 [29 April 2025]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elrexfio."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00420-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00420-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00420-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:44:42Z","timestamp":1773668682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00420-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00420-3","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kirsten J.M. van Nimwegen, Mustafa Oguz, Ra\u00fal Morana, and Joris Diels work for Johnson & Johnson. The authors report no other conflicts of interest in this communication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This letter is a response to a previously conducted cost-effectiveness analysis and does not contain any new studies within human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}